ABSK-091 is under clinical development by Abbisko Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ABSK-091’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ABSK-091 is under development for the treatment of solid tumors, advanced refractory lymphoma, metastatic urothelial cancer, multiple myeloma, gastric cancer and ovarian cancer. The drug candidate is administered orally as a tablet. It acts by targeting fibroblast growth factor receptor 1, 2 and 3 (FGFR 1/2/3).
It was under development for the treatment of solid tumors including breast cancer, metastatic non-small cell lung cancer, muscle invasive bladder cancer (MIBC), epithelial solid tumours, locally advanced and metastatic transitional cell carcinoma urinary tract cancer, including bladder cancer and transitional cell carcinoma (urothelial cell carcinoma). It was also under development for the treatment of relapsed or refractory recurrent malignant glioma, gastric cancer, and gastroesophageal (GE) junction adenocarcinomas.
Abbisko Therapeutics overview
Abbisko Therapeutics (Abbisko) is a biopharmaceutical company. It discovers and develops of novel medicines to the treatment of cancers and other diseases. Its pipeline immuno-oncology small molecule modulators include ABSK011, ABSK021, ABSK003, ABSK004, and ABSK005 reactivating tumor-specific immune response and human immune system to fight against cancer cells; ABSK006 for the treatment of diabetes. It owns an integrated research and development center in Shanghai Zhangjiang Hi-Tech Park to conduct immune-oncology drug development activities. The company is funded by healthcare investors such as Lilly Asia Ventures, Sinopharm Capital, Jianxin Capital, and TF Capital. Abbisko is headquartered in Shanghai, China.
For a complete picture of ABSK-091’s drug-specific PTSR and LoA scores, buy the report here.